July 31, 2025
A Contract Research Organization (CRO) is a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. CROs offer a wide range of services, including:
Working with a traditional CRO can offer many advantages. However, there are also potential drawbacks to consider. Here's a breakdown of the pros and cons:
Pros |
Cons |
---|---|
Expertise and Experience |
Loss of Control |
Cost Efficiency |
Quality Variability |
Speed and Scalability |
Cost Overruns |
Regulatory Knowledge |
Data Ownership and Access |
Global Reach |
Cultural and Communication Barriers |
Focus on Core Business |
Dependency Risk |
We embed proactive oversight into every phase of clinical development—ensuring quality, compliance, and control from protocol development to final submission.
Our global regulatory expertise empowers Sponsors to confidently navigate complex requirements, reducing risk and accelerating timelines.
There are no cookie-cutter models—our systems, partnership models, team structures, and quality frameworks are tailored to each Sponsor’s unique needs and program goals.
We design and implement quality systems that ensure GxP compliance, streamline vendor management, and support inspection readiness.
We build strong, collaborative, and transparent partnerships—maximizing value while minimizing risk through structured governance and communication.
From regulatory strategy to clinical operations, data management, statistical programming and biostatistics, medical information, and pharmacovigilance, ProPharma delivers comprehensive support under one roof.
Discover how ProPharma can support your clinical development journey as a full-service CRO. Contact us today to learn more.
This blog post has been updated since its original published date: October 18, 2018
TAGS: Clinical Research Solutions Contract Research Organization (CRO) Clinical Trials
May 25, 2021
The involvement of Medical Monitoring (MM) and Data Safety Monitoring Boards (DSMB) in trials has been somewhat unknown to individuals outside of clinical circles. That is, until media attention...
November 11, 2019
When pharmaceutical companies launch a clinical trial or reach a certain phase of Clinical Development, with only the support of their in-house employees, the additional workload often becomes too...
May 16, 2021
By the time the drug development process gets to Phase 3, it seems reasonable to assume that the chance of failure is relatively low. After all, the entire early-development process is at least...